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ABSTRACT 27 
 28 
The epidemiology and the clinical implication of human parvovirus 4 (PARV4) in 29 
human populations is still under evaluation. The distribution of PARV4 DNA was 30 
determined in cohorts of French haemodialysis and lung transplant patients. Plasma 31 
samples (n=289) were tested for PARV4 by real-time PCR assay (ORF2), and 32 
amplification products selected at random were sequenced. Analysis of available 33 
serological and biological markers was also undertaken. Fifty-seven samples out of 34 
185 (30.8%) were positive for PARV4 DNA in the cohort of haemodialysis patients. A 35 
higher prevalence of the virus was identified in patients with markers of HBV 36 
infection. PARV4 was also identified in 14 out of 104 samples (13.5%) from lung 37 
transplant recipients, with no clear-cut association with available clinical markers. 38 
Point mutations located on the zone of real-time detection were identified for some 39 
amplification products. This study describes the detection of PARV4 in the blood of 40 
haemodialysis and lung transplanted patients with significant difference in prevalence 41 
in these two cohorts. Further studies will be needed in order to understand better 42 
both the potential implication in host health and the natural history of this virus. 43 
 44 
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INTRODUCTION 49 
 50 
 Parvovirus 4 (PARV4) is a virus discovered recently belonging to the family 51 
Parvoviridae [Jones et al., 2005]. Identified initially in the blood of a patient 52 
harbouring acute viral syndrome, this virus had limited sequence homology with 53 
parvovirus B19 (<30% aa similarity) despite a conserved genomic organization 54 
showing two large non-overlapping ORFs [Simmonds et al., 2008]. First studies 55 
revealed that the virus was present in the blood from intravenous drug users and 56 
individuals positive for HCV or HIV at prevalence ranging from 6% to 30%, and in 57 
cohorts of kidney transplant patients as well [Biagini et al., 2008; Fryer et al., 2006; 58 
Fryer et al., 2007; Lurcharchaiwong et al., 2008; Vallerini et al., 2008]. PARV4 had 59 
been also identified in individuals without apparent pathology like blood donors (1%-60 
24%), and in blood products negative for parvovirus B19 DNA [Fryer et al., 2007; 61 
Lurcharchaiwong et al., 2008; Touinssi et al., 2010; Vallerini et al., 2008]. Genetic 62 
diversity of the virus is poorly known, but was extended recently to highly divergent 63 
animal variants identified in domestic (cow, pig) and wild (baboon, chimpanzee) 64 
species [Adlhoch et al., 2010; Lau et al., 2008; Sharp et al., 2010]. Interestingly, 65 
these studies demonstrated high prevalence values (up to 40%) for these PARV4-66 
related animal viruses. 67 
Another member of Parvoviridae family identified recently, human Bocavirus (HBoV) 68 
[Allander et al., 2005], had been more investigated and is suspected to be associated 69 
with wheezing and respiratory disease, mainly in young children [Brown, 2010]. 70 
Despite these advances, the natural history and the clinical role of these new viruses, 71 
and more particularly that of PARV4, remain unknown to a large extent. 72 
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 5 
Aim of this study consisted in the evaluation of PARV4 DNA prevalence in two 73 
different cohorts of haemodialysis patients and lung transplant recipients, combined 74 
with the analysis of available serological and biological markers. An additional 75 
investigation of HBoV DNA in lung transplant patients was also performed. 76 
 77 
 78 
MATERIALS AND METHODS 79 
 80 
Clinical samples 81 
 Two hundred and eighty-nine plasma samples originating from two cohorts of 82 
in-patients from south-eastern France were analyzed retrospectively:  83 
i) 185 haemodialysis patients (mean age 64 years; sex ratio 1.37 (men:women), 84 
mean duration of dialysis 30±28 months) from the Nephrology and Renal Transplant 85 
Centre, Conception Hospital (Marseille) (date of sampling: 2007);  86 
ii) 104 adult lung transplant recipients (mean age 42 years, sex ratio 0.73) 87 
transplanted between October 2005 and August 2008, and followed at the Lung 88 
Transplant Centre of the University Hospital of Marseille (date of sampling: from  89 
June 2007 to December 2008); blood samples were not available before 90 
transplantation. 91 
Information relating to the presence of specific antibodies to HCV, HBV, HIV, and 92 
HBs antigen in the plasma samples tested was collected. Of the 185 haemodialysis 93 
patients, 22 tested positive for HCV, 75 for HBV, 4 for HIV, and 5 for HBsAg. Of the 94 
104 lung transplant recipients, only 2 tested positive for a serological marker of HCV. 95 
 Blood samples were collected in vacuum tubes (Vacutainer, SST, Becton 96 
Dickinson, Meylan, France), centrifuged, and plasma aliquots were stored at -80°C 97 
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 6 
prior to DNA extraction. Total nucleic acids were extracted from 1 ml of plasma by 98 
using the MagNA Pure LC instrument (Roche Diagnostics, Meylan, France), as 99 
described previously [Biagini et al., 2008; Touinssi et al., 2010]. 100 
 101 
PARV4 PCR assay 102 
 Samples were screened for the presence of PARV4 DNA by real-time PCR 103 
(StepOne Plus, Applied Biosystems, Courtaboeuf, France) using a TaqMan detection 104 
system located on the ORF2 of the viral genome. Primers used were PARV4Fwd (5’-105 
CTAAGGAAACTGTTGGTGATATTGCT-3’) and PARV4Rev (5’-106 
GGCTCTCCTGCGGAATAAGC-3’), in combination with fluorogenic probe PARV4-N 107 
(5’-FAM-TCCTACYGCCCSCTCCTCCTTCTT-TAMRA-3’) [Touinssi et al., 2010]. 108 
 Amplification reactions were performed using 5 µl of extracted nucleic acids in 109 
a 20 µl reaction volume (TaqMan Fast Universal PCR kit, Applied Biosystems) 110 
according to manufacturer’s instructions. The amplification conditions were 95°C for 111 
20 seconds, followed by 50 cycles of 95°C for 1 second and 60°C for 20 seconds.  112 
 The sensitivity of the TaqMan assay was estimated at 10 copies of PARV4 113 
DNA per reaction using dilutions of a synthetic template corresponding to the target 114 
sequence (103 nt) [Biagini et al., 2008; Touinssi et al., 2010]. 115 
 116 
HBoV PCR assay 117 
 A real-time PCR assay for HBoV DNA located on the non-structural protein 118 
(NP-1) gene was further applied to samples belonging to the lung transplant cohort. 119 
Primers used were STBoNP-1f (5’-AGCATCGCTCCTACAAAAGAAAAG-3’) and 120 
STBoNP-1r (5’-TCTTCATCACTTGGTCTGAGGTCT-3’), in combination with 121 
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 7 
fluorogenic probe STBoNP-1pr (5’-FAM-AGGCTCGGGCTCATATCATCAGGAACA-122 
TAMRA-3’) [Tozer et al., 2009].  123 
 Amplification conditions were identical as those adopted for PARV4 detection. 124 
The detection limit of the real-time PCR assay was 10 copies of HBoV DNA per 125 
reaction [Tozer et al., 2009]. 126 
 127 
Sequence analysis 128 
 Real-time PARV4 and HBoV amplification products (from negative or positive 129 
samples, n=15 when available) were chosen at random in both cohorts tested, and 130 
analysed by agarose gel electrophoresis. Positive PCR products were excised and 131 
purified from agarose (Qiaquick Gel extraction kit, Qiagen, Courtaboeuf, France), 132 
cloned into the pGEM-T Easy Vector System (Promega, Charbonnieres les Bains, 133 
France) and further sequenced on both strands with M13 universal primers (BigDye 134 
Terminator v1.1 Sequencing Kit, Applied Biosystems) on an ABI PRISM 3130XL 135 
genetic analyzer (Applied Biosystem, Courtaboeuf, France). 136 
Sequences were compared with those deposited in the GenBank database 137 
using NCBI’s online BLAST2 program (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 138 
 139 
 140 
RESULTS 141 
 142 
Haemodialysis patients 143 
 Among the 185 samples tested, 30.8% (n=57) were positive for PARV4 DNA 144 
using the real-time approach described. Analysis of serological markers revealed that 145 
PARV4 DNA was detectable in 27.3% (6/22) and 38.7% (29/75) of patients positive 146 
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 8 
for HCV and HBV, respectively. PARV4 DNA was further identified in 60% (3/5) of 147 
patients positive for HBsAg, but not in any of the samples positive for HIV (n=4). The 148 
titre of PARV4 DNA in the positive samples was low (<500 copies/ml of plasma). 149 
No specific correlation was found between PARV4 viraemia and duration of dialysis 150 
or other available biological/clinical markers. 151 
 152 
Lung transplant patients 153 
 PARV4 DNA was detected in 13.5% plasma samples (14/104), including one 154 
of the two patients with HCV positive pretransplant viraemia who received 24 weeks 155 
treatment with pegylated interferon alfa plus ribavirin, with a rapid virological 156 
response and a negative viraemia before transplantation. A low titre of PARV4 DNA 157 
(<500 copies/ml) was also noted. Patients with positive sera for PARV4 DNA were 158 
transplanted for cystic fibrosis (n= 8), emphysema (n=1), alpha 1 antitrypsin 159 
deficiency (n=1), pulmonary fibrosis (n= 3), sarcoidosis (n=1). 160 
Dating of positive samples ranged from 1 (day of transplant procedure) to 1097 days 161 
after the allograft with a median of 206 days. No other serological marker was 162 
identified in the cohort studied. No difference in clinical outcome and survival was 163 
noted between recipients positive for PARV4 and those who were negative. 164 
In order to analyse tentatively the time-course of infection in relation to patients 165 
positive for PARV4 DNA, additional serial plasma samples obtained at ±6 months, 166 
with respect to the date of initial positive detection, were investigated when available. 167 
In each case (n=3, on average), attempts to detect PARV4 DNA in these samples 168 
remained unsuccessful. 169 
 Real-time PCR approach directed toward HBoV DNA gave no positive signal 170 
in any of the samples tested. 171 
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 172 
 173 
 174 
Genetic variability 175 
 Positive real-time PARV4 amplification products selected at random (n=15 and 176 
n=14 for haemodialysis patients and lung transplant recipients cohorts, respectively) 177 
were confirmed by analysis on agarose gel electrophoresis, whereas negative 178 
samples did not shown any amplification pattern. Amplification products confirmed 179 
their PARV4 origin following cloning and sequencing. Most of them exhibited 100% 180 
nucleotide identity with the PARV4 prototype isolate (GenBank accession no. 181 
AY622943) in this region, while three samples exhibited a point mutation (Fig. 1). 182 
 Absence of amplification was confirmed for each of the negative real-time 183 
HBoV amplification products analyzed. 184 
 185 
 186 
DISCUSSION 187 
 188 
 The real distribution and implication of PARV4 in humans is still under 189 
investigation. Using the same molecular approach, the detection of PARV4 in about 190 
20% of individuals without proven pathology like blood donors was reported recently, 191 
suggesting a non-negligible dispersion of the virus in the population [Touinssi et al., 192 
2010]. This study demonstrates that about 31% of a cohort of patients in 193 
maintenance haemodialysis is infected with PARV4. Analysis of serological markers 194 
characterising the cohort tends to confirm that the prevalence of the virus would be 195 
higher in individuals showing, at least for HBV, hepatitis-related markers of infection. 196 
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Such findings would be in accordance with the lower prevalence (13.5%) identified 197 
here in the cohort of lung transplanted patients, in which HCV, HBV and HIV markers 198 
were hardly absent due to the preliminary selection of patients undergoing lung 199 
allograft. However, the fact that this prevalence value was largely lower than that 200 
identified in the normal population was unexpected and possibly due to undiscovered 201 
aspects of PARV4 infection with respect to the immunosuppressive treatment of 202 
patients. 203 
 HBoV DNA was not identified in the cohort of adult lung transplant recipients. 204 
This would confirm its preferential implication in respiratory diseases of young 205 
children, even if many aspects of its natural history remain to be clarified [Schildgen 206 
et al., 2008]. 207 
 A low titre of PARV4 viral particles (<500 copies/ml) was identified in all 208 
positive samples identified in both cohorts. This is an agreement with previous 209 
studies relating generally mild PARV4 levels in blood samples, although values 210 
reaching up to 106 copies/ml were reported as well [Fryer et al., 2006; Fryer et al., 211 
2007; Biagini et al., 2008; Touinssi et al., 2010]. In addition, the presence of 212 
serological markers of HCV or HBV did not modify significantly the titre of viral 213 
particles of the positive samples in the study. It is conceivable, however, that 214 
fluctuations in viraemia would occur according to the immune status of the host, and 215 
that additional serial samples tested negative here in the case of lung transplant 216 
patients may represent periods of lowest replication of the virus, leading to 217 
undetectable levels in blood. 218 
 It was also shown that point mutations may be identifiable in the short genomic 219 
zone dedicated to PARV4 detection. This is in agreement with a recent study 220 
demonstrating notable differences in the detection of the virus, even if two slightly 221 
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different real-time approaches were used [Touinssi et al., 2010]. It is obvious that 222 
detection strategies correlate directly with the progressive estimation of the real 223 
genetic diversity of the virus. The fact that new, divergent, human and animal 224 
variants were identified recently highlights the need to optimize detection methods 225 
consistently. 226 
This study demonstrates that haemodialysis and lung transplant patients could 227 
be infected by PARV4, extending the spectrum of viral infections identifiable in these 228 
cohorts [Alpers and Kowalewska, 2007; Fischer, 2008]. Many aspects characterizing 229 
PARV4 are still largely unknown: both natural history and implication in host health, 230 
along with its genetic diversity and real dispersion in human and animal species need 231 
to be address in a near future. Interestingly, some aspects of this virus would be 232 
close to those identified in another viral family identified thirteen years ago, 233 
Anelloviridae [Biagini, 2009], which biology remains largely misunderstood. 234 
 235 
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Fig. 1. Alignment of PARV4 partial sequences showing location of point mutations in 292 
the zone of real-time detection. HDx and LTx : sequences identified from 293 
haemodialysis and lung transplant patients, respectively (GenBank accession nos 294 
HM802325-27). Grey area : nucleotide sequence targeted by the real-time probe. 295 
Lowercase letters : 5’/3’ ends of real-time primers. 296 
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